08 October 2024
: Case report
A Rare Complication of Cannabinoid Hyperemesis Syndrome
Challenging differential diagnosis, Unusual or unexpected effect of treatment
Hallie E. Knight12BEF, Abhinav Singla3CDEF, Michael Smerina4ACD, Melissa P. Cortes4CD, Tatjana Gavrancic4CD, Deborah A. Baumgarten5D, Adrian G. Dumitrascu
DOI: 10.12659/AJCR.945106
Am J Case Rep 2024; 25:e945106
Table 1. Laboratory test results.
Test | Value | Reference range |
---|---|---|
Hemoglobin, g/dL | 16.5 | 11.6–15.0 |
White blood cell count, ×10/L | 9.0 | 3.4–9.6 |
Platelets, ×10/L | 355 | 157–371 |
Sodium, mmol/L | 140 | 135–145 |
Potassium, mmol/L | 3.3 | 3.6–5.2 |
Chloride, mmol/L | 94 | 98–107 |
Bicarbonate, mmol/L | 28 | 22–29 |
Serum urea nitrogen, mg/dL | 8 | 6–21 |
Creatinine, mg/dL | 0.57 | 0.59–1.04 |
Glucose, mg/dL | 91 | 70–140 |
Albumin, g/dL | 5.2 | 2.5–5.0 |
Total bilirubin, mg/dL | 1.4 | ≤1.2 |
Direct bilirubin, mg/dL | 0.4 | 0.0–0.3 |
Alanine aminotransferase, U/L | 105 | 7–45 |
Aspartate aminotransferase, U/L | 95 | 8–43 |
Alkaline phosphatase, U/L | 67 | 35–104 |
Total protein, g/dL | 8.5 | 3.5–5.0 |
Lipase, U/L | 18 | 13–60 |
Thyrotropin, mIU/L | 0.0 | 0.5–4.3 |
Free thyroxine, ng/dL | 1.4 | 1.0–1.6 |
Total iron-binding capacity, µg/dL | 179 | 250–400 |
Ceruloplasmin, mg/dL | 14.6 | 20–51 |
Smooth muscle antibody | Negative | Negative |
Antinuclear antibody, U | 0.1 | ≤1.0 |
Mitochondrial antibody, U | <0.1 | <0.1 |
Tissue transglutaminase antibody, U/mL | <1.2 | <4.0 |
Hepatitis A antibody | Positive | Negative |
Hepatitis A IgM | Negative | Negative |
Hepatitis B surface antibody | Indeterminate | Negative |
Hepatitis B surface antigen | Negative | Negative |
Hepatitis Bc antibody | Negative | Negative |
Hepatitis C antibody | Negative | Negative |
HIV antigen/antibody | Negative | Negative |